Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: a pre-specified analysis of the EMPACT-MI trial
Aims In the EMPACT-MI trial, empagliflozin reduced heart failure (HF) hospitalizations but not mortality in acute myocardial infarction (MI). Contemporary reports of clinical event rates with and without type 2 diabetes mellitus (T2DM) in acute MI trials are sparse. The treatment effect of empaglifl...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2024
|
| In: |
European journal of heart failure
Year: 2025, Jahrgang: 27, Heft: 3, Pages: 577-588 |
| ISSN: | 1879-0844 |
| DOI: | 10.1002/ejhf.3548 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ejhf.3548 Verlag, kostenfrei, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.3548 
|
| Verfasserangaben: | Mark C. Petrie, Jacob A. Udell, Stefan D. Anker, Josephine Harrington, W. Schuyler Jones, Michaela Mattheus, Tomasz Gasior, Peter van der Meer, Offer Amir, M. Cecilia Bahit, Johann Bauersachs, Antoni Bayes-Genis, Vijay K. Chopra, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, and Javed Butler |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1920470069 | ||
| 003 | DE-627 | ||
| 005 | 20260107141237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ejhf.3548 |2 doi | |
| 035 | |a (DE-627)1920470069 | ||
| 035 | |a (DE-599)KXP1920470069 | ||
| 035 | |a (OCoLC)1528043501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Petrie, Mark C. |e VerfasserIn |0 (DE-588)1361232129 |0 (DE-627)1920470131 |4 aut | |
| 245 | 1 | 0 | |a Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes |b a pre-specified analysis of the EMPACT-MI trial |c Mark C. Petrie, Jacob A. Udell, Stefan D. Anker, Josephine Harrington, W. Schuyler Jones, Michaela Mattheus, Tomasz Gasior, Peter van der Meer, Offer Amir, M. Cecilia Bahit, Johann Bauersachs, Antoni Bayes-Genis, Vijay K. Chopra, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, and Javed Butler |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Erstmals veröffentlicht: 26. Dezember 2024 | ||
| 500 | |a Gesehen am 25.03.2025 | ||
| 520 | |a Aims In the EMPACT-MI trial, empagliflozin reduced heart failure (HF) hospitalizations but not mortality in acute myocardial infarction (MI). Contemporary reports of clinical event rates with and without type 2 diabetes mellitus (T2DM) in acute MI trials are sparse. The treatment effect of empagliflozin in those with and without T2DM in acute MI is unknown. Methods and results A total of 6522 patients with acute MI with newly reduced left ventricular ejection fraction (LVEF) to <45%, congestion, or both, were randomized to empagliflozin 10 mg or placebo. The primary endpoint was time to first HF hospitalization or all-cause death. Rates of endpoints with and without T2DM and the efficacy and safety of empagliflozin according to T2DM status were assessed. Overall, 32% had T2DM; 14% had pre-diabetes; 16% were normoglycaemic; 38% had unknown glycaemic status. Patients with T2DM, compared to those without T2DM, were at higher risk of time to first HF hospitalization or all-cause death (hazard ratio [HR] 1.44; 95% confidence interval [CI] 1.06-1.95) and all-cause death (HR 1.70; 95% CI 1.13-2.56). T2DM did not confer a higher risk of first HF hospitalization (HR 1.22, 95% CI 0.82-1.83). Empagliflozin reduced first and total HF hospitalizations, but not all-cause mortality, regardless of presence or absence of T2DM. The safety profile of empagliflozin was the same with and without T2DM. Conclusion Patients with acute MI, LVEF <45% and/or congestion who had T2DM were at a higher risk of mortality than those without T2DM. Empagliflozin reduced first and total HF hospitalizations regardless of the presence or absence of T2DM. | ||
| 650 | 4 | |a Acute myocardial infarction | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Empagliflozin | |
| 650 | 4 | |a Heart failure | |
| 700 | 1 | |a Udell, Jacob A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harrington, Josephine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jones, W. Schuyler |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mattheus, Michaela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gasior, Tomasz |e VerfasserIn |4 aut | |
| 700 | 1 | |a van der Meer, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Amir, Offer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bahit, M. Cecilia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bauersachs, Johann |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bayes-Genis, Antoni |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chopra, Vijay K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Januzzi, James L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lopes, Renato D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rossello, Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schou, Morten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zieroth, Shelley |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Sumin, Mikhail |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bhatt, Deepak L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hernandez, Adrian F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of heart failure |d Oxford : Oxford University Press, 1999 |g 27(2025), 3, Seite 577-588 |h Online-Ressource |w (DE-627)306658291 |w (DE-600)1500332-2 |w (DE-576)081985983 |x 1879-0844 |7 nnas |a Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes a pre-specified analysis of the EMPACT-MI trial |
| 773 | 1 | 8 | |g volume:27 |g year:2025 |g number:3 |g pages:577-588 |a Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes a pre-specified analysis of the EMPACT-MI trial |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ejhf.3548 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u http://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.3548 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20250325 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 20 | ||
| 999 | |a KXP-PPN1920470069 |e 4692361212 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"2024","dateIssuedKey":"2024"}],"recId":"1920470069","language":["eng"],"id":{"doi":["10.1002/ejhf.3548"],"eki":["1920470069"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Erstmals veröffentlicht: 26. Dezember 2024","Gesehen am 25.03.2025"],"name":{"displayForm":["Mark C. Petrie, Jacob A. Udell, Stefan D. Anker, Josephine Harrington, W. Schuyler Jones, Michaela Mattheus, Tomasz Gasior, Peter van der Meer, Offer Amir, M. Cecilia Bahit, Johann Bauersachs, Antoni Bayes-Genis, Vijay K. Chopra, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, and Javed Butler"]},"title":[{"title_sort":"Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes","subtitle":"a pre-specified analysis of the EMPACT-MI trial","title":"Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes"}],"relHost":[{"part":{"issue":"3","pages":"577-588","text":"27(2025), 3, Seite 577-588","year":"2025","volume":"27"},"origin":[{"dateIssuedKey":"1999","publisherPlace":"Oxford ; Amsterdam [u.a.] ; Oxford [u.a.] ; Oxford","publisher":"Oxford University Press ; Elsevier Science ; Oxford Univ. Press ; Wiley","dateIssuedDisp":"1999-"}],"pubHistory":["1.1999 -"],"disp":"Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes a pre-specified analysis of the EMPACT-MI trialEuropean journal of heart failure","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 07.01.25"],"title":[{"title_sort":"European journal of heart failure","subtitle":"journal of the Working Group on Heart Failure of the European Society of Cardiology","title":"European journal of heart failure"}],"recId":"306658291","titleAlt":[{"title":"EJHF"}],"id":{"doi":["10.1002/(ISSN)1879-0844"],"eki":["306658291"],"zdb":["1500332-2"],"issn":["1879-0844"]},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"given":"Mark C.","role":"aut","roleDisplay":"VerfasserIn","family":"Petrie","display":"Petrie, Mark C."},{"role":"aut","given":"Jacob A.","display":"Udell, Jacob A.","family":"Udell","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Anker","display":"Anker, Stefan D.","role":"aut","given":"Stefan D."},{"role":"aut","given":"Josephine","roleDisplay":"VerfasserIn","family":"Harrington","display":"Harrington, Josephine"},{"role":"aut","given":"W. Schuyler","roleDisplay":"VerfasserIn","family":"Jones","display":"Jones, W. Schuyler"},{"role":"aut","given":"Michaela","roleDisplay":"VerfasserIn","family":"Mattheus","display":"Mattheus, Michaela"},{"display":"Gasior, Tomasz","family":"Gasior","roleDisplay":"VerfasserIn","role":"aut","given":"Tomasz"},{"role":"aut","given":"Peter","roleDisplay":"VerfasserIn","display":"van der Meer, Peter","family":"van der Meer"},{"given":"Offer","role":"aut","roleDisplay":"VerfasserIn","display":"Amir, Offer","family":"Amir"},{"display":"Bahit, M. Cecilia","family":"Bahit","roleDisplay":"VerfasserIn","role":"aut","given":"M. Cecilia"},{"role":"aut","given":"Johann","family":"Bauersachs","display":"Bauersachs, Johann","roleDisplay":"VerfasserIn"},{"family":"Bayes-Genis","display":"Bayes-Genis, Antoni","roleDisplay":"VerfasserIn","role":"aut","given":"Antoni"},{"given":"Vijay K.","role":"aut","display":"Chopra, Vijay K.","family":"Chopra","roleDisplay":"VerfasserIn"},{"role":"aut","given":"James L.","roleDisplay":"VerfasserIn","display":"Januzzi, James L.","family":"Januzzi"},{"roleDisplay":"VerfasserIn","display":"Lopes, Renato D.","family":"Lopes","given":"Renato D.","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Ponikowski","display":"Ponikowski, Piotr","given":"Piotr","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Rossello, Xavier","family":"Rossello","given":"Xavier","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Schou","display":"Schou, Morten","given":"Morten","role":"aut"},{"given":"Shelley","role":"aut","roleDisplay":"VerfasserIn","family":"Zieroth","display":"Zieroth, Shelley"},{"given":"Martina","role":"aut","display":"Brückmann, Martina","family":"Brückmann","roleDisplay":"VerfasserIn"},{"given":"Mikhail","role":"aut","family":"Sumin","display":"Sumin, Mikhail","roleDisplay":"VerfasserIn"},{"family":"Bhatt","display":"Bhatt, Deepak L.","roleDisplay":"VerfasserIn","role":"aut","given":"Deepak L."},{"given":"Adrian F.","role":"aut","roleDisplay":"VerfasserIn","display":"Hernandez, Adrian F.","family":"Hernandez"},{"role":"aut","given":"Javed","roleDisplay":"VerfasserIn","display":"Butler, Javed","family":"Butler"}]} | ||
| SRT | |a PETRIEMARKEMPAGLIFLO2024 | ||